...
首页> 外文期刊>Aesthetic plastic surgery >Comparative Study of UMA Jeunesse Classic ? and UMA Jeunesse Ultra ?
【24h】

Comparative Study of UMA Jeunesse Classic ? and UMA Jeunesse Ultra ?

机译:经典恐怖的比较研究? 和一个超杰尼塞尔?

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction The emergence of hyaluronic acid dermal fillers with lidocaine has transformed the minimally invasive treatment of wrinkles, lines and folds of the face. Patients can be treated quickly, painlessly and without the need for large doses of lidocaine. Therefore, it is important to scientifically evaluate the merits of lidocaine-containing products over those without. Methods The two products, with (UJU) and without lidocaine (UJ), were randomly injected into nasolabial folds of 75 healthy volunteers with varying skin types in a split face study, age ranging 26–60?years. Only 73 subjects completed the follow-up. There were 68 females and 5 males with medium-to-deep nasolabial folds. All subjects were randomly injected with the two products on one or the other side of the face. Patients were followed up for 9?months. Results Both products achieved significant improvement in the wrinkle severity score. Overall results were slightly better with UJU due to ease of injection, lack of pain and avoidance of topical or parenteral anaesthetic. In all other respects, differences in clinical data were not statistically significant. UJU_(?)was preferred by patients and injectors due to less pain during and after injection as compared to UJ_(?)( P ?
机译:引言具有利多卡因的透明质酸皮肤填料的出现转化了面部皱纹,线和褶皱的微创治疗。患者可以快速,无痛,无需大剂量的利多卡因治疗。因此,重要的是科学地评估含Lidocaine的产品的优点。方法使用(UJU)和没有利多卡因(UJ)的两种产品被随机注入75个健康志愿者的鼻球褶皱,在分裂面书中发生不同的皮肤类型,年龄范围为26-60岁。只有73个科目完成后续行动。有68名女性和5个男性,中小型鼻球褶皱。将所有受试者随机注入两侧或另一侧的两种产品。患者随访9个月。结果两种产品在皱纹严重程度得分中取得了显着改善。由于易于注射,缺乏疼痛和局部或肠胃外麻醉剂,uju总体结果与uju略微好。在所有其他方面,临床数据的差异在统计学上没有统计学意义。 uju _(?)患者和喷射器是优选的,因为与UJ _(α)相比,注射期间和后较小而疼痛较小(p≤0.0001)。两种产品的早期和晚期并发症的总体率相似。产品之间的维护持续时间也表现出相似性。在大多数情况下维持最佳美学效果超过9?几个月,但30-50岁的患者患者做得更好。 uju的患者可接受率要高得多。结论本研究中的临床资料表明,与UJ和UJU的中微鼻褶皱的绩效和结果的绩效和结果非常相似。然而,用UJU的治疗提供了增强的患者舒适性,并且是患者和注射器的优选。证据我本期刊要求提交人向每篇文章分配一定程度的证据。有关这些基于证据的药物评级的完整描述,请参阅内容表或在线指示给作者www.springer.com/00266。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号